Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 10/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454535 | 0.90 | CCR1 (0.48) | CCR1F10EPHX2RAB9AALDH1A1 | |
| SCHEMBL13108480 | 0.84 | CCR1 (0.52) | CCR1F10EPHX2RAB9AALDH1A1 | |
| SCHEMBL3450101 | 0.80 | CCR1 (0.48) | CCR1F10EPHX2RAB9ACCR3 | |
| SCHEMBL3448743 | 0.80 | CCR1 (0.48) | CCR1F10EPHX2RAB9ACCR3 | |
| SCHEMBL3448904 | 0.80 | CCR1 (0.48) | CCR1F10EPHX2RAB9AALDH1A1 | |
| SCHEMBL3455074 | 0.79 | F10 (0.40) | CCR1F10 | |
| SCHEMBL3448458 | 0.79 | CCR1 (0.47) | CCR1F10EPHX2RAB9AUTS2R | |
| SCHEMBL3447440 | 0.78 | CCR1 (0.48) | CCR1F10EPHX2RAB9AMAPK14 | |
| SCHEMBL3449981 | 0.78 | CCR1 (0.48) | CCR1EPHX2RAB9AUTS2R | |
| SCHEMBL3451858 | 0.76 | F10 (0.51) | CCR1F10EPHX2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CCR1 2570/4885F10 22/4885EPHX2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.